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CHARACTERIZING THE ROLES OF NEUTRAL CERAMIDASE IN CISPLATIN-
INDUCED KIDNEY INJURY 
Sophia M. Sears 
August 15, 2019 
 Cisplatin is a commonly used chemotherapeutic agent with a dose-limiting 
nephrotoxicity. 30% of patients given cisplatin develop acute kidney injury (AKI). 
AKI increases risk of chronic kidney disease (CKD) development and mortality. 
Patients that don’t develop clinical AKI are still at risk for long term declines in 
renal function. Currently, there are no FDA approved agents to treat or prevent 
cisplatin-induced kidney injury (CDDP-KI). In this study, we demonstrated that 
neutral ceramidase (nCDase) knockout provides protection from AKI in the high-
dose model of CDDP-KI. However, in the repeated low dose cisplatin (RLDC) 
model of injury and we found nCDase knockout does not prevent development of 
CKD. We also observed that nCDase knockout reduces induction of ER stress in 
the single high-dose model but not in the RLDC model. This study suggests there 
are unique mechanisms of RLDC induced kidney injury which may have hindered 
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ACUTE KIDNEY INJURY 
Epidemiology and Defining AKI 
 Acute kidney injury (AKI) is defined as a rapid decrease in renal function 
characterized by a decrease in glomerular filtration rate (GFR) and an increase in 
retained waste products.[1] It is one of the most common life-threatening 
conditions associated with hospital admissions. Since 2002, it has been 
estimated that 25% of patients admitted to the hospital develop AKI. [2, 3] 
Development of AKI increases risk of mortality 5.5-6.5 fold compared to similarly 
ill patients who do not develop AKI.[4]  
As our population ages, incidence of AKI is increasing. Age alone 
increases the likelihood of AKI development, but the increase in complications 
such as hypertension, cardiovascular disease, and chronic kidney disease also 
increase vulnerability to AKI. Therapeutic interventions such as surgery and 
chemotherapy put patients at risk for AKI as well. All of these factors have 
contributed to the steadily increasing incidence of AKI, particularly among elderly 
hospitalized patients.[2] Financially, the rise in AKI cases is problematic. In 2005, 
the financial burden of AKI was estimated to be $10 billion in additional cost to 
the health care system in the United States.[4] 
The exact prevalence of AKI has been difficult to monitor due to its broad 
definition and variable methods of measuring renal function. An important 
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function of the kidney is to filter out nitrogenous waste products from the blood to 
be excreted in the urine. A decline in GFR can therefore be observed by an 
increase in circulating nitrogenous compounds. Serum creatinine and blood urea 
nitrogen (BUN) are two products that can be measured to estimate GFR. 
Increased concentrations of these products in the blood corresponds to a 
decreased renal clearance. Therefore, serial measurements of serum creatinine 
and BUN can provide an idea of declining kidney function.[4] Until recently, there 
had not been set quantitative standards of kidney function that described an AKI 
diagnosis. 
In order to provide more clarity, the RIFLE classification 
(Risk/Injury/Failure/Loss/End-stage renal disease) and AKIN classification (Acute 
Kidney Injury Network) were published providing measurable criteria to define 
stages of kidney injury based on measurements of serum creatinine and urine 
output.[2] The RIFLE scale classifies kidney injury cases by severity into 
categories of risk, injury, or failure. It further classifies outcomes of kidney injury 
as either loss of function or end stage renal disease. By RIFLE definitions, AKI 
corresponds to a doubling in patient serum creatinine from baseline and a 50% 
reduction in GFR with urine output dropping below 0.5 ml/kg/hr for 12 hours. 
Renal function must decline to these levels in 1 to 7 days and remain below 
these standards for at least 12 hours.[5, 6] 
 In 2007, the AKIN classification was published to expand on the RIFLE 
classification. AKIN standards do not require estimation of baseline serum 
creatinine and considers diagnosis of AKI only after achieving adequate 
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hydration and excluding urinary obstruction. AKI is diagnosed as stage 1, 2, or 3 
based on the increase of serum creatinine within 48 hours, rather than from an 
estimated baseline. Stage 1, 2, and 3 on the AKIN scale corresponds to the risk, 
injury, and failure levels of RIFLE. Stage 2 AKI is defined as an increase of 0.3 
mg/dl serum creatinine and a drop in urine output below 0.5 mg/kg/hr for 12 
hours.[5] In the clinic, patients are often diagnosed with AKI using a combination 
of RIFLE and AKIN classifications determined by the Kidney Disease Improving 
Global Outcomes (KDIGO) group. Diagnosis is based on either a 0.3 mg/dl 
increase of serum creatinine within 48 hours or a doubling of serum creatinine 
from estimated baseline occurring within 7 days.[5] 
Biomarkers of AKI 
 Although serum creatinine has been relied on in clinics for diagnosing AKI, 
it is not a perfect indicator. Serum creatinine does not become elevated until 24-
72 hours after a renal insult. It is also affected by factors such as age, race, sex, 
body weight, metabolism, and protein intake.[2] BUN also has limitations in 
determining GFR, as it is also affected by factors other than renal injury and 
spikes after renal damage has already occurred.[4] As the incidence of AKI 
development is increasing with an aging population, it has become more and 
more important to develop new biomarkers with more sensitivity and specificity. 
Ideally, new biomarkers would be more specific to kidney damage and would 
indicate injury is occurring at earlier timepoints. Two newer biomarkers of AKI 
include neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury 
marker 1 (Kim-1). 
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 NGAL gained attention as a biomarker of AKI when it was observed to be 
elevated in the kidney following ischemic and nephrotoxic insults in animal 
studies.[7] It was first identified in neutrophils, but it also functions as a rapid 
response protein to tissue injury. NGAL has antibacterial effects through iron 
scavenging properties and promotes epithelial growth through an unknown 
mechanism.[8] NGAL has had mixed success in predicting AKI events clinically. 
Although it is a sensitive marker for kidney tissue damage, it has also been 
shown to elevate in other acute and chronic inflammatory conditions. 
Development of an assay specific for kidney secreted NGAL would increase its 
specificity as a marker of AKI.[7, 8] 
 Kim-1 is a cell surface receptor in epithelial and lymphoid/myeloid cells. Its 
expression also increases significantly during AKI in proximal tubule cells.[8] It 
has been suggested that during AKI, proximal tubule cells lose their polarity and 
Kim-1 is secreted into the interstitium.[9] Although larger studies for validation are 
needed, Kim-1 shows promise as a specific and sensitive marker for subclinical 
AKI detection. It has been approved by the US FDA as a biomarker for preclinical 
drug development.[10] 
Pathology of AKI 
There are many underlying causes of AKI. AKI can arise due to prerenal, 
intrinsic, or postrenal conditions. Prerenal injury is due to decreased renal 
prefusion or volume depletion. Intrinsic injury is caused by direct damage or 
disruption within the kidneys. Postrenal injury occurs when there is insufficient 
urine drainage distal to the kidneys. While prerenal and postrenal injuries can 
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often be corrected with repletion of intravascular volume or removal of a urinary 
blockage, intrinsic AKI must resolve with time and often requires renal 
replacement therapy such as dialysis.[11] 
Intrinsic AKI is the most common form of AKI acquired in hospitalized 
patients, accounting for up to 70% of cases.[4] Intrinsic injury is divided into 
further categories based on where kidney damage is occurring. There are 
glomerular, interstitial, tubular, and vascular causes of intrinsic AKI. AKI is most 
often caused by acute tubular necrosis.[11] Eighty to ninety percent of the cases 
of acute tubular necrosis are a result of an ischemic or nephrotoxic insult. 
Despite the name, cell death is not always present in AKI caused by acute 
tubular necrosis and can include damage caused by sublethal changes in tubule 
cells. AKI involves several pathophysiological processes including endothelial 
damage and vascular impairment, immune response, and tubular cell death.[12] 
There processes orchestrate AKI development in phases of initiation, extension, 
maintenance, and recovery.[4]  
 In the initiation phase, the ischemic or nephrotoxic insult causes functional 
damage to tubule epithelial cells. Renal blood flow decreases as a result of 
injury, causing a decrease in available cellular ATP. This limited energy supply 
further damages epithelial and endothelial cells, triggering the release of 
cytokines and chemokines to initiate the inflammatory cascade. Epithelial cells 
will also undergo morphological changes, leading to a loss of the brush border 
membrane and begin undergoing apoptosis or necrosis. After death, these cells 
often slough off and cause tubular obstruction.[4] 
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 The extension phase defines the subsequent continued hypoxia and 
inflammatory response. Hypoxia is exacerbated by damage to renal vascular 
endothelial cells. Inflammatory and profibrotic cells begin infiltrating and 
proliferating in response to the earlier released signals. Tubule cells continue to 
die in this phase, leading to a continued decline in GFR.[4] 
 In the maintenance phase, repair processes begin. GFR halts its decline 
as tubule cells begin dedifferentiation, migration, and proliferation to re-establish 
structural integrity. Renal blood flow begins to return to normal. Cellular repair 
and reorganization begin the process of restoring organ function.[4] 
  In the recovery phase, renal function recovers. Epithelial cells re-establish 
polarity and return to normal function. Inflammatory and profibrotic cells are 
cleared. The extent to which renal function returns can vary depending on 
several factors. It is also hypothesized that there may be chronic impairment of 
vasculature and sublethal changes in tubule epithelial cells making the kidney 
more sensitive to additional insults.[4] 
 Episodes of AKI can lead to many different outcomes. Acute symptoms 
include disturbances in acid-base and electrolyte homeostasis, uremia, and fluid 
overload.[3] Currently, there are no FDA approved agents to prevent or treat AKI. 
Patients are often required to stay in the hospital to receive primarily supportive 
care. Patients’ intravascular volume, electrolyte balance, and cardiac function are 




Following an incident of AKI, the kidney has the ability to repair tissue 
damage and return to normal function. However, long term studies have shown 
that patients who have suffered an AKI event have increased risk of developing 
chronic kidney disease (CKD), proteinuria, and cardiovascular mortality.[13] One 
study found that development of AKI requiring dialysis made patients 28 times 
more likely to develop CKD and doubled the risk of mortality.[14] As more 
research is done, the link between AKI and CKD has become increasingly noted.  
 
CHRONIC KIDNEY DISEASE 
Epidemiology and Defining CKD 
 CKD is defined as a gradual loss of kidney function accompanied by 
kidney damage, usually measured by albuminuria. CKD is typically accompanied 
by interstitial fibrosis, glomerulosclerosis, and chronic inflammation.[13] A 
diagnosis of CKD encompasses a diverse range of conditions with different 
causes, severity, and rates of progression. Typically, CKD is diagnosed when 
patients progress to the failure stage of the RIFLE classification and remain there 
for over 3 months.[15] At this stage there is generally a 75% reduction in GFR. 
Since no treatment is available for CKD, patients must be put on dialysis. This 
can slow the progression of kidney disease, but patients will eventually progress 
to loss of kidney function (complete loss of function for more than 4 weeks) and 
then to end stage renal disease (complete loss of function for more than 3 
months). Patients at this stage eventually require a renal transplant to survive.[5] 
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CKD prevalence has been steadily increasing over the past 20 years.[16] 
As of 2017, CKD was estimated to affect 13.4% of people globally.[17] In the US, 
there is estimated to be 400 new cases of CKD per million people per year.[15] 
This increasing prevalence is concerning due to the detrimental impact on 
patients as well as the high societal cost of CKD. Generally, CKD development is 
associated with old age, hypertension, diabetes, cardiovascular disease, and 
obesity.[15] Recently, more studies have been done revealing that multiple 
incidences of AKI also increase the likelihood of CKD development.[18, 19]  
As mentioned earlier, AKI involves high levels of tubule cell death. 
Following AKI, the kidney initiates normal wound healing processes to recover 
from the initial insult. Although the repair processes following AKI can recover 
renal function, in some cases the kidney undergoes what has been termed 
maladaptive repair, which can lead to the development of CKD.[13] 
Maladaptive Repair 
Maladaptive repair refers to the phenomenon by which normal repair 
processes go awry and result in progressive damage. The primary features of 
maladaptive repair are cell cycle arrest, profibrotic cytokine production, 
myofibroblast accumulation, chronic immune cell activation, and chronic vascular 
impairment.[13] Maladaptive repair begins in the maintenance phase of AKI, 
when tubule cells are beginning to respond to renal injury. In this stage, it has 
been demonstrated that surviving tubule cells are pushed into the cell cycle in 
order to proliferate and re-establish the proximal tubule structure.[20] This 
adaptive proliferation is necessary for healing, but in maladaptive repair tubule 
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cells undergo G2/M cell-cycle arrest and senescence.[13] In this arrested state 
tubule cells secrete profibrotic factors such as transforming growth factor beta  
(TGFβ) and connective tissue growth factor (CTGF) downstream of c-Jun N-
terminal kinase (JNK) activation.[12]  
The process of cell-cycle arrest and subsequent JNK activation leading to 
fibrosis has been primarily worked out in models of ischemia-reperfusion injury 
(IRI). Yang et. al. demonstrated that pharmacologic inhibition of JNK as well as 
p53 (preventing cell-cycle arrest) reduces fibrosis following ischemic injury. This 
study also found that pharmacologic induction of G2/M cell cycle arrest in HK-2 
cells increased JNK activation and upregulated profibrotic gene expression.[21] 
These studies demonstrate that cell cycle arrest can lead to JNK activation and 
cytokine production. It also illustrates that this process is involved in development 
of renal fibrosis following ischemic injury.  
The profibrotic cytokines produced by senesced tubule cells promotes 
production of activated myofibroblasts.[12] A major hallmark of maladaptive 
repair is the appearance of these activated myofibroblasts, which are the main 
contributors of collagen deposition and development of the fibrotic matrix.[13] 
Myofibroblasts display characteristics of both smooth muscle cells and 
fibroblasts. In normal wound healing their role is to deposit ECM in order to 
maintain the integrity or injured tissue, allowing for proliferation and healing. In 
maladaptive repair, myofibroblasts are chronically stimulated leading to over 
production of ECM. The ECM laid down in renal fibrosis is primarily composed of 
type I and III collagen cross-linked by fibronectin.[22] Myofibroblasts have been 
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speculated to differentiate from several different precursors.[23] Although it is still 
a subject with much controversy, resident fibroblasts and pericytes are thought to 
be major contributors with mesenchymal stem cells and bone-marrow derived 
fibrocytes also having a role.[13] 
In addition to profibrotic cytokine production, injured tubule cells also 
release pro-inflammatory cytokines and chemokines through mechanisms 
including activation of toll-like receptor (TLR) signaling. TLRs are expressed on 
tubule epithelial cells. Exogenous and endogenous ligands associated with injury 
can activate the proinflammatory TLR response leading to production of tumor 
necrosis factor alpha (TNFα), monocyte chemoattractant protein 1 (MCP-1), and 
interleukin 6 (IL-6) to recruit immune cells to the injured kidney.[12] Neutrophils, 
monocytes/macrophages, and leukocytes are among the most responsive 
infiltrates to the kidney. These immune cells are important in the normal process 
of recovery to attenuate early injury as well as clear damaged debris. However, 
chronic immune cell activation can mediate effects of maladaptive repair, 
particularly through chronically activated macrophages.[13] 
Macrophages make up a large and diverse population of immune cells. 
They are a group of phagocytic cells that differentiate from monocytes upon 
environmental stimulation. In kidney injury, both renal resident and bone-marrow 
derived infiltrating macrophages respond to injury. Resident macrophages arise 
from embryonic macrophages that migrate to the kidney during development. 
These resident cells help maintain renal homeostasis by clearing cellular debris 
and aiding in tissue remodeling. Infiltrating macrophages are recruited to the 
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kidney following injury. Both resident and infiltrating macrophages can adopt 
different phenotypes to perform a variety of functions.[24] 
Functionally speaking, macrophages display a spectrum of subtypes. For 
simplicity, we will refer to the extreme ends of the spectrum as M1 and M2. M1 
macrophages appear in the kidney rapidly following injury. These cells are 
generally considered “pro-inflammatory.” Macrophages are polarized to an M1 
phenotype by pro-inflammatory cytokines and danger signals.[25] Upon 
polarization, they continue to produce proinflammatory cytokines to recruit other 
immune cells. They also produce reactive oxygen and nitrogen species to 
destroy pathogenic particles. This is done largely by inducible nitric oxide 
synthase (iNOS) which is a characteristic marker of M1 function.[24] M1 
macrophages are thought to play a role in infection clearance, but they are also 
known to exacerbate acute renal injury.[25] 
M2 macrophages appear later in kidney injury and are thought of as 
having a “pro-repair” phenotype. There are several different subsets of M2 
macrophages that differentiate in response to different environmental stimuli. 
TGFβ is one of the major cytokines that drives M2 polarization. M2 macrophages 
are thought to suppress inflammation and promote tissue repair.[25] Arginase-1 
(Arg-1) is characteristically expressed by M2 macrophages and is used to 
produce building blocks for the ECM. M2 macrophages also secrete TGFβ 
creating a positive feedback signaling loop.[24] Although M1 macrophages may 
still be present in chronic injury, development of renal fibrosis is associated with 
an M1 to M2 phenotype transition.[25]  
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The complex role of macrophages in kidney injury has been studied by 
several groups. In a model of IRI it was demonstrated that global depletion of 
macrophages via administration of liposome clodronate attenuated development 
of renal fibrosis. Adoptive transfer of M2 macrophages after global depletion 
reversed this beneficial effect while M1 transfer did not. This suggests a role for 
M2 macrophages in the development of fibrosis post-IRI.[26] Another study went 
on to demonstrate that global depletion of macrophages with liposomal 
clodronate after development of AKI following IRI resulted in failure to recover 
from injury.[27] These studies demonstrate the importance of coordinated M1 
and M2 responses to kidney injury to promote proper healing and repair. Chronic 
activation of either subset likely can exacerbate maladaptive repair processes. 
The immune cell responses and wound healing processes observed after 
a renal insult suggests repairing tubule structure is the most immediate response 
to kidney injury. However, removing causes of injury is also of high importance in 
recovery from AKI. As mentioned earlier, vascular endothelial damage in AKI 
leads to renal hypoxia. In the extension phase of AKI, this endothelial injury and 
dysfunction leads to continued impairment of kidney oxygen delivery. Studies 
show repeated injury promoting tubule cell proliferation may impede the repair of 
endothelial cells. Tubule proliferation is associated with high levels of TGFβ and 
low levels of vascular endothelial growth factor (VEGF) in the kidney. 
Differentiation of pericytes into myofibroblasts trigged by damaged tubule cells 
also removes vital trophic support of endothelial cells. This suggests that tubular 
repair may inadvertently impair vasculature repair.[13] Repeated AKI insults and 
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maladaptive repair therefore also lead to chronically impaired vasculature, further 
promoting renal fibrosis. 
All the above processes demonstrate how maladaptive repair can result 
from a chronic activation of injury responses. Endothelial damage promotes 
continued injury leading to tubule G2/M cell-cycle arrest, profibrogenic cytokine 
production, chronic immune cell activation, and activation of myofibroblasts. 
These processes promote chronic inflammation, fibrosis, and vascular rarefaction 
characteristic of CKD.[13] 
Fibrosis and Resolution 
 Fibrosis is defined as an excessive accumulation of ECM commonly 
caused by chronic or repeated injury. Excessive ECM deposition disrupts tissue 
architecture and decreases renal function.[22, 28] Typically, ECM production is a 
normal part of wound healing. It is vital to maintaining tissue integrity following an 
injury. Improper resolution of fibrosis is what leads to chronic disease. Wound 
healing can be defined in phases that involve the same processes as 
maladaptive repair up until the final phase. The inflammatory phase refers to the 
death of tubule cells prompting infiltration of immune cells to clear debris and 
promote new tissue formation.[22] The proliferative/effector phase involves the 
proliferation of tubule cells to reestablish barrier function as well as the 
differentiation and proliferation of myofibroblasts to produce ECM and maintain 
tissue integrity. The final phase of wound healing is maturation. In this stage, the 
ECM is degraded and profibrogenic myofibroblasts are removed. Repeated or 
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chronic injury often leads to inadequate maturation, resulting in long term organ 
fibrosis.[28] 
It should be noted that there are two main forms of ECM: basement 
membrane ECM and interstitial ECM. Basement membrane ECM provides 
support for epithelial and endothelial cells. It is made up of collagen IV and 
laminins. Interstitial ECM is secreted primarily by myofibroblasts and has a more 
rigid, cross-linked structure. Interstitial ECM is thought to be more fibrotic, made 
up of fibrillar collagen type I and III cross-linked by fibronectin. Basement 
membrane and interstitial ECM are thought to play different roles in the 
development of renal fibrosis.[22]  
 Resolution of organ fibrosis in the maturation phase requires three 
components: eradicating the cause of injury, degradation and removal of the 
fibrotic ECM, and elimination of myofibroblasts.[22, 28] Promoting resolution of 
organ fibrosis to treat CKD is a rising area of research. One mechanism for 
targeting resolution of fibrosis is increasing the degradation of ECM. A potential 
mechanism for increasing the degradation of ECM is through metalloproteinases 
(MMPs). MMPs are thought to be the most important enzymes involved in 
collagen degradation. They comprise a large family of proteins. Although MMPs 
are important in degradation of fibrotic matrix, they can also promote fibrosis 
through activities unrelated to ECM degradation.[22]  
 The role of MMPs in renal fibrosis is not straight forward. Nishida et. al. 
examined the role of matrix metalloproteinase 2 (MMP2) in development of renal 
fibrosis following unilateral ureteral obstruction. They found that pharmacologic 
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inhibition of MMP2 attenuated development of fibrosis. Interestingly, MMP2 
inhibition also lead to decreased macrophage infiltration in the injured kidney. 
This was hypothesized to be the mechanism of protection.[29]  
Wang et. al. also demonstrated that mice lacking matrix 
metalloproteinase-9 (MMP9) developed less fibrosis in a model of unilateral 
ureteral obstruction. MMP9 knockout mice displayed less disruption of tubule 
basement membrane following injury. They also had decreased expression of 
fibronectin and less total collagen. They hypothesized that MMP9 deficiency 
provided protection primarily by preventing basement membrane 
degradation.[30] Other studies on MMP9 have led to the hypothesis that MMP9 
degradation of basement membrane ECM promotes tubule epithelial to 
myofibroblast transition. Promoting this differentiation suggests that MMP9 plays 
a profibrogenic role.[31, 32] 
Other studies have also demonstrated the complexity of MMPs in renal 
fibrosis. Another strategy that has been tried to promote fibrotic ECM degradation 
is inhibition of tissue inhibitors of metalloproteinases (TIMPs). TIMPs bind to 
MMPs and target them for macrophage engulfment, preventing their activity.[22] 
Kawamoto et. al. used TIMP3 knockout mice in a model of unilateral ureteral 
obstruction. Although these mice had some alterations in kidney structure, TIMP3 
deficiency did not prevent development of renal fibrosis.[33]  
These studies indicate that MMPs and TIMPs play multiple roles in the 
kidney besides regulating degradation of fibrotic ECM. The balance of MMPs and 
TIMPs can regulate immune cell responses, myofibroblast accumulation, and 
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signaling pathways such as TGFβ. It is clear that MMPs and TIMPs serve 
purposes beyond degradation of ECM. Our lack of understanding of their many 
complex roles make them a difficult target for prevention of renal fibrosis.[28]  
As myofibroblasts are thought to be the source of increased ECM in 
development of fibrosis, eliminating myofibroblasts is another area of focus. 
Myofibroblasts may be removed via apoptosis, senescence, dedifferentiation, or 
reprogramming.[22] Zeisberg et. al. attempted to promote myofibroblast 
dedifferentiation to attenuate renal fibrosis in a nephrotoxic serum nephritis 
model. This group used bone morphogenic protein 7 (BMP-7), a member of the 
TGFβ superfamily, in an attempt to reverse the epithelial to myofibroblast 
transition occurring in progressive renal disease. In vitro they demonstrated that 
BMP-7 reversed TGFβ-induced changes in tubule epithelial cells. They therefore 
hypothesized that BMP-7 was promoting processes that opposed the epithelial to 
myofibroblast transition and would be capable of preventing myofibroblast 
accumulation. They then demonstrated that BMP-7 treatment in vivo slowed 
progression of renal fibrosis, but it could not reverse disease pathogenesis.[34] 
Although this study showed promise, the plasticity of myofibroblasts make them a 
difficult target for treatment. 
Although fibrosis shows potential for resolution in the context of wound 
healing, it is accepted that all organs have a “point of no return” in which capacity 
for resolution is lost. In most clinical cases, the attempts to reverse developed 
organ fibrosis have not had much success.[28] Targeting the extension phase of 
AKI seems to hold the most potential for preventing the AKI to CKD transition. 
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Currently, there is no cure for CKD. As CKD is a progressive disease, most 
therapies are aimed at supportive care and slowing the progression of functional 
decline. Medication aimed at blood pressure and glycemic control are commonly 
used.[35] Even with these treatments patients will eventually progress to end-




Clinical Uses of Cisplatin 
 As previously mentioned, the most common cause of intrinsic AKI is acute 
tubular necrosis caused by ischemic or nephrotoxic insults. Nephrotoxic side 
effects of drugs cause around 20% of hospital and community acquired AKI 
cases.[36] One of the most common class of agents that induce nephrotoxic 
acute tubular necrosis is nephrotoxic chemotherapies.[11] It is estimated that 
60% of hospital-acquired AKI is caused by nephrotoxicity of chemotherapy.[37] 
Cisplatin (cis-diamminedichloridoplatinum(II)) is an inorganic platinum-
based drug that was approved by the FDA as an anticancer agent in 1978.[38] It 
is currently a standard component of therapy used to treat many solid-organ 
cancers such as head, neck, lung, testis, ovary, and breast.[39] The major 
mechanism of action of cisplatin involves binding DNA, forming adducts, and 
forcing cancer cells to undergo apoptosis or cell-cycle arrest. It has shown a 
great amount of success as an anticancer agent, particularly in treating testicular 
and ovarian cancer. Since the FDA approval of cisplatin, the rate of remission for 
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testicular cancer has increased from 5% to around 80%.[38] The effectiveness of 
cisplatin however, is largely reduced by its dose-limiting nephrotoxicity.  
 In an effort to bypass this toxicity, several analogs of cisplatin such as 
carboplatin and oxaliplatin have been developed. Although these compounds do 
have less nephrotoxicity, they are much less effective in killing many types of 
cancer cells. One study demonstrated that the concentration of carboplatin had 
to be 20-40 fold higher than that of cisplatin to form the same amount of DNA 
adducts.[38] Due to its high level of activity, cisplatin is still commonly used in the 
clinic today. 
 Around 30% of patients who receive cisplatin develop AKI.[39] Since there 
are no approved agents to treat AKI, development of the injury requires treatment 
to be suspended. Patients are monitored in hopes that renal function will recover 
in 2-4 weeks. Following recovery, patients are often switched to a different 
treatment regimen.[39] The nephrotoxicity associated with cisplatin prevents it 
from being as effective in treating cancer as it could be. Since its approval, 
research has shed light on the mechanism of cisplatin’s nephrotoxicity in hopes 
of finding a way to prevent these effects. 
Mechanisms of Nephrotoxicity 
 Patients typically receive cisplatin as either a bolus intravenous injection 
or slow intravenous infusion.[40] As the kidney receives a large portion of blood 
flow, it encounters high concentrations of cisplatin. Cisplatin is filtered from the 
blood into the kidney through both glomerular filtration and tubular secretion. As 
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the blood is filtered by the kidney, active accumulation of cisplatin within renal 
parenchymal cells occurs. Cisplatin concentrations eventually become greater in 
the kidney then in the blood.[39]  
The high affinity copper transporter (Ctr1) and the organic cation 
transporter (OCT2) are both highly expressed basolaterally on proximal tubule 
cells and facilitate the uptake of cisplatin by the kidney.[41] While Ctr1 is 
ubiquitously expressed, OCT2 has much higher levels of renal expression.[37] 
Ctr1 has been shown to facilitate uptake of cisplatin by cancer cells, making it a 
poor target for prevention of renal toxicity.[41] OCT2 expression is more specific 
to renal tubule cells and studies have demonstrated that OCT2 knockout and 
pharmacologic inhibition with cimetidine confers some resistance to cisplatin-
induced kidney injury.[42, 43] Additional studies also demonstrated that co-
administration of cisplatin with cimetidine did not affect antitumor efficacy.[44] On 
the apical membrane, multidrug and toxin extrusion 1 (MATE1) is expressed and 
is capable of transporting cisplatin from tubule cells into the lumen for excretion. 
Studies have shown that MATE1 knockout mice are more sensitive to AKI and 
have elevated levels of platinum in the kidney following high-dose cisplatin 
treatment.[45] 
Prior to transport, metabolism of cisplatin begins in circulation with 
glutathione conjugation, possibly by glutathione-S-transferase.[39, 41] These 
conjugates are then cleaved by gamma glutamyl transpeptidase (GGT) to form 
cysteinyl-glycine-conjugates.[39] Some studies have demonstrated the inhibition 
of glutathione-S-transferase and GGT can attenuate cisplatin nephrotoxicity in 
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mice, but the effect on tumoricidal activity is unknown.[37] Aminopeptidases 
further metabolize cisplatin by cleaving it into a cysteine conjugate. The cysteine 
conjugate is then transported into proximal tubule cells where it is converted to a 
highly reactive thiol by cysteine-S-conjugate-beta-lyase.[37, 39] 
 As mentioned above, the primary mechanism of cisplatin’s anti-cancer 
activity is thought to be through DNA damage. Several studies have further 
demonstrated that mitochondrial DNA is the major target of damage.[39] In 
aqueous environments cisplatin exchanges its chloride ions for water molecules, 
forming a positively charged electrophile. This can lead to preferential 
accumulation in negatively charged mitochondria.[39, 46] Nevertheless, 
accumulation of reactive cisplatin metabolites in the cell leads to formation of 
DNA, RNA, and protein adducts.[47] These adducts contribute to nephrotoxicity 
via many of the same mechanisms by which cisplatin kills cancer cells. Cisplatin-
induced nephrotoxicity involves proximal tubule cell damage, increased oxidative 
stress, inflammatory response, and vascular injury.[41, 47]  
Cisplatin induces proximal tubule cell damage via several mechanisms. 
The most prominent mechanism of injury is activation of cell death pathways.[39, 
41, 47] Cisplatin has been demonstrated to induce necrosis as well as intrinsic-, 
extrinsic-, and endoplasmic reticulum (ER) stress associated pathways of 
apoptosis.[41, 47] Wei, Dong, & Dong demonstrated the importance of intrinsic-
apoptotic signaling in cisplatin nephrotoxicity using genetic manipulation of pro-
apoptotic BCL-associated X (BAX). They demonstrated that BAX knockout 
conferred resistance to cisplatin-induced kidney injury in mice by decreasing 
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cytochrome c release and the number of apoptotic cells.[48] This study indicates 
that tubule cell intrinsic apoptosis is a large contributor to nephrotoxicity. 
Wei et. al. went on to demonstrate a role for tumor protein 53 (p53) in 
intrinsic apoptosis induction in cisplatin nephrotoxicity. p53 has been known to 
play a role in apoptotic induction following DNA damage. Their group observed 
that cisplatin treatment lead to increased phosphorylation of p53. They then 
showed that inhibition of p53 with pifithrin-α and genetic deletion of p53 
attenuated cisplatin-induced kidney injury in mice.[49] This study demonstrates 
that DNA damage is likely a major contributor to intrinsic apoptotic induction in 
cisplatin nephrotoxicity. 
Cisplatin has also been reported to promote cell death independently of its 
DNA damaging actions. Mandic et. al. observed nucleus-independent apoptotic 
signaling triggered by cisplatin. When enucleated cells were treated with 
cisplatin, ER stress was induced. This ER stress then triggered caspase 
activation and apoptosis. Other DNA damaging agents were not able to induce 
this same response, indicating that cisplatin had unique cytosolic targets.[50] 
Cisplatin-induced tubular damage sets off the pathological processes of AKI 
discussed earlier. 
Cisplatin induces many other forms of sublethal damage involving cell 
cycle dysregulation, activation of mitogen activated protein kinase (MAPK) 
signaling, mitochondrial dysfunction, ER stress, and autophagy induction.[39, 41, 
47] ER stress and autophagy are of particular relevance to this work. ER stress is 
caused by an accumulation of misfolded proteins. Cisplatin has been speculated 
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to cause ER stress through adduction to cytosolic targets.[50] The level and 
duration of ER stress determines if cells are forced to undergo apoptosis or to 
adapt and survive. One method of adapting to ER stress is through upregulation 
of autophagy.[51] Autophagy is a form of cellular “self-eating” that can be both 
protective and detrimental. Studies have shown that cisplatin-induced AKI is 
associated with induction of autophagy. In acute models of injury this induction is 
thought to be protective.[47] Autophagy can help reduce levels of cisplatin-
induced apoptosis by ameliorating effects of cellular damage from oxidative 
stress and mitochondrial dysfunction.[52] In chronic kidney injury the role of 
autophagy is more controversial. It has been argued that long-term upregulation 
of autophagy could also contribute to renal damage.[53] These mechanisms of 
sublethal damage demonstrate that even if cisplatin does not induce cell death, it 
can still have negative impacts on cellular homeostasis. 
Inflammation is another mediator of cisplatin nephrotoxicity that has been 
repeatedly studied in cisplatin-induced kidney injury (CDDP-KI). Cisplatin 
treatment is associated with an upregulation of many different proinflammatory 
cytokines and chemokines such as interleukin 1 beta (IL-1β), IL-6, MCP-1, and 
TNFα.[41, 47] One mechanism of production of these signals is via toll-like 
receptor signaling. Injury to renal epithelial cells induces release of damage 
associated molecular patterns (DAMPs) which activate toll-like receptor 4 
(TLR4). TLR4 activation leads to production of chemokines and cytokines, 
including TNFα, that lead to upregulation of endothelial adhesion molecules and 
attraction of inflammatory cells.[39] Ramesh and Reeves have shown that TNFα 
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is a major inflammatory mediator in CDDP-KI. They utilized TNFα knockout mice 
and GM6001, a pharmacological inhibitor of TNFα, to demonstrate that inhibition 
of TNFα signaling attenuated CDDP-KI. They also demonstrated that TNFα 
inhibition decreased production of other inflammatory mediators, indicating it 
plays a central role in activation of the cytokine response.[54] The cytokine 
response attracts immune cell infiltrates to the injured kidney. Neutrophils, 
macrophages, T cells, and dendritic cells appear to be the largest responders to 
cisplatin induced injury.[39, 47] 
Vascular damage is another mediator of CDDP-KI. This damage is 
orchestrated in a variety of ways including alteration of renal blood flow and 
direct toxicity to endothelial cells.[47] Early vasoconstriction in response to 
cisplatin has been thought to be an initiator of vascular injury. Although the cause 
of vasoconstriction is not quite clear, it results in a decrease in GFR and 
promotes development of a hypoxic environment. Hypoxic conditions further 
contribute to the tubule cell death and inflammation. Vascular damage, tubule 
cell death, and inflammation are all connected and work together to orchestrate 
the nephrotoxicity of cisplatin.[4]  
The nephrotoxicity of cisplatin has been observed in patients since its 
introduction. Many strategies have been applied to prevent this toxicity from 
occurring. Hydration regimens and use of diuretics such as furosemide and 
mannitol have been explored. Clinically, however, these regimens do not seem to 
prevent CDDP-KI. Current clinical guidelines recommend pre-hydration with 
0.9% saline and avoidance of diuretics.[39]  
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Models of Cisplatin Injury 
 As previously mentioned, 30% of patients who receive cisplatin develop 
AKI. They display a rapid decline in kidney function and increase in BUN or 
serum creatinine following treatment. This type of CDDP-KI is modeled in animal 
studies by using a single high dose (10-30 mg/kg) of cisplatin. Following 
treatment, mice display a significant decline in renal function and typically only 
survive 3-4 days post treatment. This model mirrors the rapid decrease in GFR 
and spike in serum creatinine defining AKI in the clinic. However, it does not 
allow for long term studies of the effects of CDDP-KI.[38, 55]  
 70% of patients who receive cisplatin do not develop AKI by clinical 
criteria. Recent studies have revealed that these patients may still be at risk for 
long term renal effects from cisplatin. Skinner et. al. followed pediatric patients 
treated with cisplatin that did not develop clinical AKI. They found that 10 years 
following treatment 11% had a decreased GFR and 15% were showing signs of 
nephrotoxicity.[56] 
In order to address this issue, Sharp et. al. developed a new animal model 
to study CDDP-KI. This model involves repeated low doses of cisplatin (7-9 
mg/kg) once a week for four weeks. Mice treated with this dosing regimen can 
survive 6 months following treatment. Immediately following treatment mice do 
not show significant increases in BUN; however, at 6 months post-treatment mice 
do have significantly elevated BUN levels compared to vehicle treated mice. This 
indicates mice have progressive loss of kidney function following cisplatin 
treatment without showing clinical signs of AKI during the dosing window.[57] 
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 These models together allow us to study patients on either end of the 
CDDP-KI spectrum. The acute, high dose model is characterized by high levels 
of tubular apoptosis and necrosis, a rapid decline in GFR, and increases in BUN 
and serum creatinine. On the other hand, the chronic, low dose model does not 
cause significant BUN or serum creatinine changes. This model seems to cause 
subclinical injury that leads to development of fibrosis following the fourth dose. 
Fibrosis worsens as mice age to 6 months post treatment, accompanied by a 
chronic infiltration of macrophages. This phenotype is more indicative of CKD 
development.[58]  
Together these models demonstrate the interconnectedness of AKI and 
CKD and how cisplatin can lead to both types of kidney injury. These models 
also depict how different biological processes can be triggered in response to 
acute or chronic cisplatin treatment. Both models should therefore be used to test 
drug candidates to prevent CDDP-KI. 
 
SPHINGOLIPIDS AND KIDNEY INJURY 
 
Sphingolipid Metabolism 
 Sphingolipids are lipid compounds that contain a sphingoid-base 
backbone. The kidney has been known to play an important role in sphingolipid 
metabolism for many years. It was originally thought that sphingolipids played 
primarily a structural role in the cell. It has since come to light that sphingolipids 
act on a number of cellular targets and are involved in many different signaling 
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pathways.[59] It has become an increasing area of interest to examine how these 
bioactive lipids effect renal physiology and how regulation of lipid levels could be 
used as a therapeutic target.[60] 
 Sphingolipid metabolism involves an abundance of enzyme-catalyzed 
reactions. At the center of this large network lies ceramide. Ceramide can be 
produced via de novo synthesis, sphingomyelin hydrolysis, or recycling of other 
complex sphingolipids. In de novo synthesis, serine palmitoyl transferase 
condenses serine and palmitoyl CoA to form 3-ketosphingosine. This product is 
then reduced to dihydrosphingosine by 3-ketoreductase. Dihydrosphingosine is 
then acylated by ceramide synthase to form dihydroceramide. Desaturase then 
desaturates dihydroceramide at the 4-5 position of the sphingoid base backbone 
to generate ceramide. Once generated, ceramide is the basis for several 
reactions generating other bioactive lipid species.[59, 61] 
 Ceramide can be used by sphingomyelin synthases to form 
sphingomyelin. It can also be phosphorylated by ceramide kinase to form 
ceramide-1-phosphate. Glycosylation of ceramide via addition of a glucose or 
galactose forms the hexosylceramides, glucosylceramide, and 
galactosylceramide, respectively. Hexosylceramides are utilized to synthesize 
more complex gylcosphingolipids and can also be broken down to regenerate 
ceramide. Ceramide can be cleaved via the action of ceramidases to form 
sphingosine, which can then be phosphorylated by sphingosine kinases 1 or 2 to 
form sphingosine-1-phosphate (S1P). Sphingosine can also be recycled back 
into ceramide as catalyzed by ceramide synthases or ceramidases. In our 
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studies, we focus on the balance of ceramide, sphingosine, and S1P. It is 
thought that the balance of these bioactive sphingolipids regulates several 
cellular processes including inflammation, reactive oxygen species production, 
and cell death. These are all processes implicated development of acute kidney 
injury and chronic kidney disease.[59, 61] 
Manipulation of Sphingolipids in Models of Kidney Injury 
 Ceramide has been considered a “pro-apoptotic” signaling lipid in the 
past.[59] In vitro, cisplatin treatment of baby mouse kidney epithelial cells 
induces ceramide generation via upregulation of de novo ceramide synthesis. 
Inhibition of ceramide synthesis protected these cells from cisplatin-induced cell 
death.[61] Our studies have also demonstrated that acute cisplatin treatment 
causes increased levels of ceramide in the kidney.[62] Taken together, these 
studies suggest that ceramide could be a key mediator of cisplatin-induced cell 
death in kidney injury. 
 Dupre et. al. used this rationale to explore the impact of inhibiting 
ceramide synthesis on kidney injury caused by acute cisplatin treatment. In this 
study, it was also observed that there were increased activities of ceramide 
synthases in the de novo synthesis pathway and acid sphingomyelinase in the 
kidney cortex following treatment of mice with cisplatin. Therefore, ceramide 
synthesis was inhibited via myriocin and amitriptyline, inhibitors of de novo 
ceramide synthesis and acid sphingomyelinase, respectively. These inhibitors 
reduced ceramide levels in the kidney following cisplatin treatment. This inhibition 
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also resulted in lower levels of BUN and serum creatinine following single, high 
dose cisplatin.[62] 
 Dupre et. al. also noted that there were increased levels of 
hexosylceramides in the kidney following cisplatin treatment of mice. It had been 
unknown whether ceramide or the shuttling of ceramide into hexosylceramides 
was promoting CDDP-KI. C10, an inhibitor of glucosylceramide synthase, was 
used to prevent this shuttling of ceramide into hexosylceramides. C10 and 
cisplatin co-treatment of mice lead to increased levels of BUN, Kim-1, and tissue 
damage. C10 also caused increased apoptosis, cell proliferation, and 
inflammatory cytokine production following cisplatin treatment. C10 and cisplatin 
co-treatment prevented hexosylceramide generation, but increased ceramide 
accumulation.[62] These data suggest a role for ceramide in apoptosis in CDDP-
KI. It also provides an example of how regulating the balance of different 
sphingolipid species can affect CDDP-KI. 
 Other groups have also explored the role of sphingolipids in acute kidney 
injury. The Okusa lab explored the role of S1P in kidney injury. S1P is known to 
bind to and signal through a family of G-coupled protein receptors known as S1P 
receptors (S1PRs). S1PR signaling was shown to be protective in models of 
acute cisplatin injury and IRI. A S1PR agonist offered protection from kidney 
injury in these models while genetic S1PR deletion exacerbated injury.[63, 64] 
Bartles et. al. also demonstrated the importance of SIP signaling in IRI. They 
subjected mice with endothelial specific S1PR deletion to ischemic injury. These 
mice sustained higher levels of injury then wild type controls. This study 
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highlights the importance of S1PR in endothelial function.[65] These studies 
demonstrate the importance of S1P signaling pathways in renal injury. 
The homeostasis of ceramide and other sphingolipids in the context of 
kidney injury is becoming increasingly recognized. In this study, we evaluate the 
effects of neutral ceramidase inhibition in the context of kidney injury both in vitro 
and in vivo. Neutral ceramidase (nCDase) is one of five ceramidases. It is named 
because it is most active at neutral pHs.[66] Although the role of nCDase in 
kidney injury has not received much attention, it has been identified as a target in 
other models of injury. Novgorodov et. al. demonstrated that nCDase inhibition 
conferred protection from traumatic brain injury by protecting cells from 
mitochondrial damage.[67] In the kidney, nCDase activity was shown to be 
elevated in models of diabetic neuropathy.[68] Taken together, these studies 
indicate that nCDase could play a pathological role in kidney injury via alteration 
of ceramide, sphingosine, and S1P balance. 
Our lab demonstrated that mouse embryonic fibroblasts (MEFs) lacking 
functional nCDase were protected from nutrient and energy deprivation induced 
cell death. nCDase knockout cells could survive cell stress due to increased 
levels of autophagy.[69] It has been demonstrated that autophagy plays a 
protective role in acute cisplatin-induced renal injury.[70] We therefore 
hypothesized that nCDase inhibition may have some effect on CDDP-KI 
development.  
 With the growing body of knowledge delineating the AKI to CKD transition 
it has become increasingly important to test prospective nephroprotective targets 
30 
 
in models of both acute injury and fibrosis development. In this study we set out 
to examine how nCDase inhibition affects kidney injury following both the acute 
high-dose cisplatin model and the repeated low dose cisplatin (RLDC) model. 
Our results indicate that repeated low dose cisplatin treatment may utilize unique 




MATERIALS AND METHODS 
 
Cell Culture 
Mouse embryonic fibroblast (MEFs) were generated and validated as previously 
described from either wild type or neutral ceramidase (nCDase)-null C57BL/6 
mice that were littermates.[69] Cells were immortalized with dominant-negative 
p53. MEFs were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS) and supplemented with L-glutamine, 
penicillin, streptomycin, and ciprofloxacin (Invitrogen). All cells were incubated at 
37°C in 5% carbon dioxide. Cells were not cultured for more than 30 doublings 
and were routinely assessed for mycoplasma using MycoSensor PCR assay kit 
(#302108, Agilent Technologies) according to the manufacturer’s protocol. 
Cell Viability Assays 
For the FBS withdrawal experiment, cells were plated in DMEM containing 10% 
FBS and antibiotics into 3 separated 96-well plates on day 1. On day 2, cells 
were washed with sterile phosphate buffered saline (PBS) and then treated with 
media at varying concentrations of FBS. On day 3, 1 plate was assessed for 24-
hour viability using Alamar Blue assay. On day 4, the 48-hour plate was 
assessed and on day 5, the 72-hour plate was assessed. For the nCDase 
inhibitor viability assay cells were plated, treated, and assessed in the same 
manner. C6-urea-ceramide (C6) and the nCDase inhibitor from Ono 
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Pharmaceutical Company (Ono) were dissolved in dimethyl sulfoxide (DMSO) 
and added to DMEM at indicated concentrations. Final DMSO concentration in 
media was kept under 1%. 
nCDase in vitro TLC Activity Assay 
Equal amounts of recombinant nCDase (gifted from Dr. Yusef Hannun, Stony 
Brook University) were incubated and treated with the indicated nCDase 
inhibitors at 0.1 μM to 100 μM. NBD-ceramide at 50 μM in 100 mM Tris with 
0.3% Triton-X-100, pH 7.5 was added to each sample. The reaction progressed 
for 10 minutes and was then stopped with 3:1 addition of equal parts 
MeOH:Chloroform. Samples were centrifuged at 15,000 rpm for 10 minutes at 
4°C. The organic phase of the reaction was extracted and dried down in a speed 
vacuum. Samples were then solubilized in 10 μL of 1:1 MeOH:Chloroform and 
spotted on a TLC plate. The plate was placed in a reaction chamber with 
90:29.5:0.5 Chloroform:MeOH:NH4OH for 1 hour to allow separation of ceramide 
and sphingosine. Plates were imaged with phosphoimager and analyzed using 
Quantity One software. This assay was modified from Tani et. al.[71] 
Animals 
Neutral ceramidase knockout mice (nCDase-/-) were gifted from Dr. Ashley 
Snider at Stony Brook University. nCDase-/- were originally generated in the 
laboratory of Dr. Richard L. Proia (NIDDK, National Institutes of Health). These 
mice were previously backcrossed for 10 generations onto a C57BL/6 
background. nCDase-/- mice were bred in-house and all experiments were 
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performed at 8-10 weeks of age. Wild type mice (C57BL/6, male, 4-weeks old) 
were either bred in house or purchased from The Jackson Laboratory and 
allowed to acclimate for 4 weeks prior to initiation of experiments. All mice were 
maintained on a 12-hour light/dark cycle and provided food and water ad libitum. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee and followed the guidelines of the American Veterinary Medical 
Association.  
Cisplatin Dosing Regimen 
Pharmacy grade cisplatin (1mg/mL in normal saline) was obtained from the 
University of Louisville Hospital pharmacy. For the high-dose study, cisplatin was 
administered at 20 mg/kg in normal saline in a total volume of 500 μL by 
intraperitoneal (i.p.) injection. Vehicle treated mice received 500 μL normal saline 
by i.p. injection. For the repeated low dose study, cisplatin was administered at 9 
mg/kg in normal saline in a total volume of 400 μL by i.p. injection once a week 
for four weeks. Vehicle treated mice received 400 μL normal saline by i.p. 
injection once a week for four weeks. All mice were administered 500 μL saline 
by subcutaneous injection 1 day prior to dose 3, 2 days after dose 3, and 1 day 
before dose 4 to prevent weight loss. All animals were injected with cisplatin at 
the same time of day as there are circadian influences on the response of the 
kidney to cisplatin. Animals were euthanized 72 hours following their final 
cisplatin injection. Upon euthanasia, blood was collected and plasma prepared 
and frozen at -80°C; urine was collected and frozen at -80°C; and kidneys were 
removed, flash frozen in liquid nitrogen, and stored at -80°C until use. A cross-
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section of one kidney was also fixed in 10% neutral buffered formalin for 
histology.        
Blood Urea Nitrogen (BUN), Serum Creatinine (SCr), and Neutrophil 
Gelatinase Associated Lipocalin (NGAL) Determination 
BUN (AMS Diagnostics, 80146) and SCr (Point Scientific Inc., C7548-120) levels 
were measured from plasma samples using the indicated kits following the 
manufactures’ instructions. ELISAs for NGAL (R&D Systems, DY1857) were 
performed on the urine as directed by the manufacturer. 
Protein Quantification and Western Blot Analysis 
Kidney tissue and cultured MEF cell pellets were homogenized in cell extraction 
buffer (Thermo Fisher Scientific) containing a Complete Protease Inhibitor 
Cocktail Tablet and Phosphatase Inhibitor Cocktail Tablets (Roche). 
Homogenates were centrifuged at 15,000 X g for 10 min at 4° C. Supernatants 
were removed and stored at -80°C. Protein concentrations were determined 
using Bradford Reagent (Bio-Rad). 40 μg of kidney homogenate protein and 20 
μg of MEF cellular protein were loaded and separated on 4–12% gradient Tris-
Glycine-SDS polyacrylamide gels. Protein was then transferred to PVDF 
membranes that were blocked in 5% (w/v) dried milk in tris buffered saline 0.1% 
Tween 20 (TBST) for 1 hour. Membranes were incubated with primary antibody 
overnight at 4°C. The next morning, membranes were washed 3 times for 5 min 
each with TBST containing 5% (w/v) dried milk. Membranes were then incubated 
for 2 hours at room temperature with secondary antibodies conjugated with 
horseradish peroxidase (1:20,000) in TBST containing 1.25% (w/v) dried milk. 
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Following 3 washes in TBST membrane proteins were detected by 
chemiluminiscence substrate.  
Antibodies 
The following antibodies were purchased from Cell Signaling (Beverly, MA): 
cleaved caspase-3 (CC3) #9664, C/EEBP homologous protein (CHOP) #2895, 
phosphorylated c-jun n-terminal kinase (p-JNK T183/Y185) #4668, c-jun n-
terminal kinase (JNK) #9258 and #9252, phosphorylated-protein kinase B (p-AKT 
S473) #4060, protein kinase B (AKT) #4691, phosphorylated-glycogen synthase 
kinase beta (p-GSK3β S9) #9322, glycogen synthase kinase beta (GSK3β) 
#9315, phosphorylated nuclear factor kappa-light-chain-enhancer of activated B 
cells (p-NF-κB S536) #3033, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) #3987, phosphorylated- eukaryotic initiation factor 2 
alpha (p-eIF2α) #3398, and light chain 3B (LC3B) #3868. Remaining antibodies 
include: fibronectin (F3648, Sigma-Aldrich), α-tubulin (SC-23948, Santa Cruz 
Biotechnology), and β-actin (A2228, Sigma-Aldrich). 
Gene Expression 
RNA was isolated using either TRIzol (Thermo Fisher Scientific) or E.Z.N.A. Total 
RNA Kit 1 (OMEGA) per manufacturer’s protocol. cDNA was synthesized with 
High Capacity cDNA Reverse Transcriptase PCR (Thermo Fisher Scientific) per 
manufacturer’s instructions. Gene-specific cDNA was quantified with real-time 
qRT-PCR using either predesigned TAQman assays or self-designed SYBR 
assays. The following TAQman primers were purchased from Thermo Fisher 
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Scientific: tumor necrosis factor alpha (TNF-α, Mm00443258_m1), interleukin-6 
(IL6, Mm00446190_m1), chemokine (C-X-C Motif) ligand 1 (CXCL1, 
Mm04207460_m1), monocyte chemotactic protein (MCP-1, Mm00441242_m1), 
arginase-1 (Arg-1, Mm00475991_m1), and the housekeeping gene beta-2-
microglobulin (B2M, Mm00437762_m1). The following primers were self-
designed: inducible nitric oxide synthase (iNOS, Invitrogen, forward: 
GAGATTGGAGGCCTTGTGTCA, reverse: TCAAGCACCTCCAGGAACGT) and 
kidney injury molecule-1 (Kim-1, Invitrogen, forward: 
AGATCCACACATGTACCAACATCAA, reverse: 
CAGTGCCATTCCAGTCTGGTTT). qRT-PCR was done with either iTaq 
Universal Probes Supermix (172-5134, Bio-Rad) or iTaq Universal SYBR Green 
Supermix (172–5124, Bio-Rad). 
Histology 
Following formalin fixation, kidney tissue was processed and embedded in 
paraffin. Kidney sections (5 m) were stained with hematoxylin and eosin (H&E) 
and periodic acid schiff (PAS). The degree of morphologic changes was 
determined by light microscopy in a blinded fashion. The following measures 
were chosen as an indication of morphologic damage to the kidney after drug 
treatment: proximal tubule degradation, loss of brush border, tubular casts, 
proximal tubule dilation, proximal tubule necrosis, presence of inflammatory cells, 
and interstitial fibrosis. These measures were evaluated on a scale from 0 to 4, 
which ranged from not present (0), mild (1), moderate (2), severe (3), and very 
severe (4).  
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Sirius Red/ Fast Green Staining 
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an 
ethanol gradient. Slides were then dipped in PBS with 0.1% Tween 20 and 
incubated for 5 minutes. Slides were washed with distilled water twice for 5 
minutes each and then incubated in 1.2% (w/v) saturated picric acid (#5860-32, 
Ricca Chemicals) containing 0.1% sirius red/direct red 80 (#365548, Sigma) and 
0.1% fast green FCF (#F7258, Sigma). Slides were then washed with 5% glacial 
acetic water until the water ran clear. Tissue samples were then dehydrated and 
fixed using Permount (#17986-01, Electron Microscopy Sciences).  
Statistical Analysis Data 
Data are expressed as means ± SEM for all experiments. Multiple comparisons 
of normally distributed continuous data were analyzed by two-way ANOVA and 
group means were compared using Tukey post-tests. Nonparametric continuous 
data were analyzed with a Kruskal-Wallis test followed by a Dunn’s multiple 
comparison test. Nominal data from pathology scoring were analyzed by 
individual Chi-squared tests. The criterion for statistical differences was p < 0.05 






nCDase knockout confers resistance to serum withdrawal in vitro. We had 
previously shown that nCDase knockout conferred resistance to ER stress- and 
nutrient deprivation- induced cell death.[69] These experiments were done with 
pharmacological agents that blocked cellular metabolism and/or directly acted on 
cellular organelles. To follow up these experiments, we also wanted to test this 
idea in a more natural model of ischemic injury. We used mouse embryonic 
fibroblasts (MEFs) grown from wild type and nCDase knockout C57BL/6 mice as 
described previously.[69] These cells were cultured in media at varying 
concentrations of fetal bovine serum (FBS) for 24, 48, and 72 hours. Cellular 
viability was monitored via measuring relative cell numbers through Alamar Blue 
fluorescence. We found that nCDase knockout cells had significantly higher 
viability at 0.625% and 0% FBS at all timepoints compared to wild type controls. 
Viability was also significantly higher at 1.25% FBS at 48 hours (Fig 1). These 
data indicate that nCDase knockout provides protection from a serum withdrawal 




















Cells were plated at 2,000 cells per well in a 96-well plate on day 1. The next day cells 
were washed with PBS then treated with the appropriate media. Viability was measured 24, 
48, and 72 hours from treatment via alamar blue assay. * denotes significance of p<0.05. 
WT indicates wild type MEFs, KO indicates nCDase knockout MEFs. 
Figure 1. Viability of nCDase knockout and wild type MEFs during FBS withdrawal. 
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nCDase knockout alters signaling pathways connected to autophagy and 
cell survival. It had previously been shown that upregulation of autophagy was 
the mechanism by which nCDase knockout provides protection from nutrient 
stress.[69] We verified that the autophagic marker LC3B was upregulated basally 
in nCDase KO cells as compared to WT cells as was previously reported by 
Sundaram et. al. We wanted to also determine if pathways that regulate 
autophagy are altered basally in cells deficient in nCDase. To this end, we 
performed western blot analysis of protein kinase B (AKT) and glycogen 
synthase kinase 3 beta (GSK3β) in MEF wild type and nCDase knockout cells. 
Data revealed upregulation of phosphorylated AKT (p-AKT) as well as increased 
phosphorylation of GSK3β (p-GSK3β) (Fig 2). The increase in p-AKT along with 
p-GSK3β follows the reported regulation of GSK3β activity, as p-AKT 
phosphorylates and inactivates GSK3β. GSK3β inactivation or inhibition has 
been reported to upregulate pro-survival autophagy.[72, 73] It has also been 
reported that inhibition of GSK3β can protect from necrotic and apoptotic cell 
death by preventing mitochondrial permeability transition.[72] Although further 
characterization is needed to suggest these pathways are essential for nCDase 
knockout mediated protection from nutrient stress, literature suggests it could 
play a role. These processes would also likely be protective in the high-dose 



























Wild type and nCDase knockout MEFs were cultured in DMEM containing 10% FBS. 
Cells were pelleted and lysed with cell extraction buffer containing protease and 
phosphatase inhibitors. 20 μg of protein were then taken for western blot analysis. WT 
indicates wild type MEFs, KO indicates nCDase knockout MEFs. 




Pharmacological inhibition of nCDase induces signaling changes as seen 
in genetically modified MEFs. In order to test whether signaling changes 
observed in nCDase knockout MEFs were due to long term compensation or 
acute inhibition of nCDase, we used two pharmacological inhibitors of nCDase in 
wild type MEF cells in vitro. C6-urea ceramide (C6) is a widely used inhibitor of 
nCDase but is known to have high levels of toxicity due to off target effects. We 
also used a newly developed nCDase inhibitor from Ono Pharmaceutical 
Company (ONO). We wanted to inhibit nCDase at a concentration that was not 
lethal to cells yet still provided adequate enzymatic inhibition. Viability of MEF 
wild type cells was assessed under treatment with a wide range of 
concentrations of both ONO and C6 drug over a period of 72 hours. The ONO 
drug was shown to be less toxic then C6 (Fig 3a and 3b). At 50 μM, ONO treated 
wild type MEFs still displayed around 50% viability. At 50 μM, C6 killed all wild 
type MEFs by 24 hours. We also observed that ONO showed some selectivity in 
killing wild type MEFs more effectively than nCDase knockouts (Fig 3a and 3b). 
This indicates ONO may be acting in a more targeted manner. We also tested 
the activity of the drugs in vitro, using a TLC enzymatic activity assay with 
recombinant nCDase (Fig 3c, Fig 3d). From these experiments, we identified a 
smaller range of concentrations where nCDase inhibition was observed. Western 
blot analysis of MEFs treated at these concentrations of inhibitor revealed that 
pharmacologic inhibition of nCDase resulted in upregulation of p-AKT, p-GSK3β, 
and LC3 as previously seen with genetic knockout of nCDase (Fig 4). This 
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suggests that these effects may be due to acute inhibition of nCDase activity and 




























(A,B) Wild type MEFs were plated at 1,000 cells per well in a 96-well plate. Ono drug 
(3a) or C6 (3b) concentrations were added the next day. Viability was monitored via 
alamar blue assay over 72 hours. WT indicates wild type MEFs, KO indicates nCDase 
knockout MEFs (C,D) nCDase inhibition was assessed using an in vitro, TLC activity 
assay of wild type MEFs treated with inhibtiors. Inhibition of ceramide conversion to 
sphingosine was observed under both Ono (3c) and C6 (3d) treatment. 
Figure 3. Viability and nCDase enzymatic activity of wild type MEFs treated with 



























Wild type and nCDase knockout MEFs were cultured for 24 hours in the presence of 
either Ono or C6 drug. Cells were then harvested and lysed in cell extraction buffer 
containing protease and phosphatase inhibitors. 20 μg of protein were then analyzed 
for each condition via western blot. WT indicates wild type MEFs, KO indicates 
nCDase knockout MEFs. 
Figure 4. Acute inhibition of nCDase confers signaling changes as seen in 
nCDase knockout MEFs. 
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Loss of nCDase confers resistance to AKI following high-dose cisplatin 
treatment. Our in vitro results above and elsewhere[69] indicated that nCDase 
knockout protects MEFs from ER stress and nutrient deprivation via upregulation 
of autophagy. Upregulation of autophagy has been reported to be protective in 
acute models of CDDP-KI.[70] In order to test the effects of nCDase on the 
development of AKI following acute, high-dose cisplatin treatment, we utilized a 
colony of C57BL/6 mice with a neo cassette inserted into the encoding gene of 
nCDase. As a result, mice homozygous for this gene produce a nonfunctional 
nCDase (nCDase -/-). We found that genetic inhibition of nCDase in vivo also 
leads to an increase in the LC3B marker of autophagy in the kidney cortex (Fig 
5). Following treatment with high dose cisplatin, nCDase -/- mice displayed 
resistance to acute kidney injury development. Kidney function as measured by 
BUN was significantly lower in nCDase -/- mice 72 hours post cisplatin treatment 
(Fig 6a). Serum creatinine (SCr) and NGAL levels also appeared lower in 
nCDase -/- mice compared to wild type although these results were not 
significant (Fig 6b, Fig 6c). nCDase -/- mice had significantly lower levels of 
tubular necrosis, cast formation, inflammatory cells, and loss of brush border as 
determined by pathology. Tubular dilation and tubule degeneration was also 
lower in nCDase -/- mice compared to wild type although these results were not 
significant (Fig 7b-g). Inflammatory cytokine production following cisplatin 
treatment was also assessed using qRT-PCR of kidney tissue. TNFα, IL6, MCP-
1, and CXCL1 levels were lower in nCDase -/- mice but were not statistically 















Renal cortex and medulla from vehicle treated wild type and nCDase -/- mice were 
harvested and prepped for western blot analysis. WT indicates wild type mice, KO 
indicates nCDase -/- mice. Experiment done by Dr. Tess Dupre. 






C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg 
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment and 
kidney injury markers were assessed. (A,B) BUN and SCr were measured from serum 
of cisplatin and vehicle treated wild type and nCDase -/- mice. (C) NGAL levels were 
assessed from urine of cisplatin and vehicle treated wild type and nCDase -/- mice. 
(D) Mouse body weight was measured each day following cisplatin treatment. * 
signifies statistically different than vehicle treated WT mice. # signifies statistically 
different than cisplatin treated WT mice. ^ signifies statistically different than vehicle 
treated KO mice. Experiment was performed by Dr. Tess Dupre, data were 
reanalyzed by Sophia Sears. 
 


































C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg 
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment. 
Renal histological changes were assessed on H&E and PAS stained sections 5 
μm thick. (A) Representative images of renal histology at 200X magnification. (B) 
Tubular necrosis, (C) loss of proximal tubule brush borders, (D) proximal tubule 
cast formation, (E) inflammatory cells, (F) tubule degeneration, and (G) tubule 
dilation were assessed as markers of histological changes. For figures (B-G), 
scoring of the sections was performed in a blinded manner by renal pathologist 
Dr. Megyesi using a scale of 0-4 (0=not present, 1=mild, 2=moderate, 3=severe, 
and 4=very severe renal histological changes in the proximal tubules). WT 
indicates wild type mice, KO indicates nCDase-/- mice. * signifies statistically 
different than vehicle treated WT mice. # signifies statistically different than 
cisplatin treated WT mice. ^ signifies statistically different than vehicle treated KO 
mice. Experiment was performed by Dr. Tess Dupre, data were reanalyzed by 
Sophia Sears. 
Figure 7. Loss of nCDase protects from high-dose cisplatin-induced 



























C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg cisplatin 
or normal saline. Mice were sacrificed 72 hours after cisplatin treatment. Relative 
expression of (A) TNFα, (B) IL6, (C) MCP-1, and (D) CXCL1 mRNA were measured via 
qRT-PCR. WT indicates wild type mice, KO indicates nCDase-/- mice.  * signifies 
statistically different than vehicle treated WT mice. # signifies statistically different than 
cisplatin treated WT mice. ^ signifies statistically different than vehicle treated KO mice. 
Experiment done by Dr. Tess Dupre, data were reanalyzed by Sophia Sears. 
Figure 8. Loss of nCDase decreases mRNA expression of inflammatory 
cytokines in the kidney following high-dose cisplatin treatment. 
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nCDase -/- mice have reduced apoptosis following high-dose cisplatin 
treatment. It is well established that the acute, high-dose model of cisplatin-
induced kidney injury causes a high level of apoptosis. This high level of cell 
death mediates the pathological changes that manifest as acute kidney injury. 
We hypothesized that nCDase -/- may mediate protection from high-dose 
cisplatin by preventing cell death, as previously seen in our in vitro models of cell 
stress. In order to assess the level of apoptosis occurring in vivo, we performed a 
western blot of cleaved caspase 3. Following cisplatin treatment nCDase -/- mice 
had no detectable expression of cleaved caspase 3 (CC3) while wild type mice 
showed increased levels of CC3 as compared to vehicle treated mice (Fig 9a). 
We also performed TUNEL staining on wild type and nCDase -/- mice following 
cisplatin treatment. We found nCDase -/- mice treated with cisplatin had 
significantly less TUNEL-positive apoptotic cells then wild type treated mice (Fig 
9b). These data indicate that nCDase -/- blocks induction of apoptotic cell death 














C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg cisplatin or 
normal saline. Mice were sacrificed 72 hours after cisplatin treatment. (A) Western blot 
analysis was performed to assess relative protein levels of cleaved caspase 3 in the renal 
cortex of mice. (B-C) TUNEL assays were performed on paraffin embedded kidney sections 
as an index of apoptosis. (B) Representative photomicrographs of TUNEL assays (final 
magnification 200X). (C) TUNEL quantification. WT indicates wild type mice, KO indicates 
nCDase-/- mice.  * signifies statistically different than vehicle treated WT mice. # signifies 
statistically different than cisplatin treated WT mice. ^ signifies statistically different than 
vehicle treated KO mice. Experiment done by Dr. Tess Dupre. 
Figure 9. Loss of nCDase attenuates high-dose cisplatin-induced apoptosis. 
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nCDase -/- mice have reduced levels of ER stress following high-dose 
cisplatin treatment. Cisplatin has been shown to induce ER stress as a 
mechanism of cell toxicity.[50] In order to assess how nCDase -/- would affect 
induction of ER stress we performed western blot analysis on wild type and 
nCDase -/- mice treated with cisplatin or vehicle. We found the nCDase -/- mice 
treated with cisplatin had reduced levels of ER stress markers p-JNK, CHOP, 
and p-eIF2α compared to wildtype mice treated with cisplatin (Fig 10). These 









C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg 
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment. 
Western blot analysis was performed to assess relative protein levels of markers 
of ER stress in the renal cortex of mice. WT indicates wild type mice, KO 
indicates nCDase-/- mice. Experiment done by Dr. Tess Dupre. 
Figure 10. Loss of nCDase attenuates high-dose cisplatin-induced ER stress. 
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Repeated low-dose cisplatin (RLDC) induces signaling pathways similar to 
nCDase -/- triggered pathways. As more information is being revealed about 
the interconnectedness of AKI and CKD, it is becoming increasingly important to 
test prospective nephroprotective agents in models of both types of injury. With 
the development of our RLDC model, we had the capability to test nCDase as a 
target for cisplatin-induced renal fibrosis and CKD. As the pathology associated 
with our RLDC model is somewhat different than what is seen in the high-dose 
model, we were unsure if nCDase -/- would mediate protection. However, upon 
analysis of wild type mice treated with RLDC we found signaling pathways were 
altered in a manner consistent with nCDase -/- mediated signaling changes in 
vitro. p-AKT, p-GSK3β, and LC3 expression was upregulated in wild type mice 
following RLDC (Fig 11). Therefore, we hypothesized that nCDase -/- may confer 








Wild type C57BL/6 mice were injected (i.p.) with either 9 mg/kg cisplatin or normal 
saline once a week for four weeks. Mice were sacrificed 72 hours following the final 
dose. Expression of the indicated proteins was evaluated from renal cortex using 
western blot.  
Figure 11. RLDC treatment of C57BL/6 mice induces changes in protein 
expression similar to those triggered by nCDase inhibition in vitro. 
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nCDase inhibition does not protect from RLDC induced kidney injury. 
C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with 9 
mg/kg cisplatin or saline once a week for four weeks. 500 μl saline was injected 
(subQ) 1 day before dose 3, two days after dose 3, and 1 day before dose 4. 
Mice were sacrificed 72 hours following the last dose. Kidney function was 
evaluated by BUN, NGAL, and Kim-1 levels. Following RLDC there appeared to 
be no difference in BUN, NGAL, or Kim-1 levels between all cisplatin treated 
groups. All cisplatin treated groups had significantly elevated BUN, NGAL, and 
Kim-1 levels compared to vehicle treated controls (Fig 12a-c). Throughout RLDC, 
mouse body weights were monitored. Saline was administered to ensure weight 
loss did not fall below 25%. All cisplatin treated mice appeared to have equal 
amounts of weight loss throughout RLDC regardless of their genotype (Fig 12d). 
Upon pathology assessment, nCDase -/-, nCDase -/+, and wild type mice 
appeared to have similar levels of damage in the measures assessed (Fig 13). 
Cisplatin treatment unexpectedly caused significant increases in tubular necrosis 
and tubular regeneration not seen in FVB mice under RLDC treatment.[57] 
Inflammatory cytokine expression following RLDC also indicated nCDase 
inhibition did not provide a protective effect. TNFα, IL6, MCP-1, and CXCL1 
mRNA expression were similar between all cisplatin treated groups (Fig 14a-d). 
We also evaluated iNOS and Arg-1 mRNA expression to assess the level of M1 
and M2 macrophages present. Genotype did not appear to influence iNOS or 
Arg-1 levels. Cisplatin treatment caused a significant decrease in iNOS 
expression and increase in Arg-1 expression as previously characterized (Fig 
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14e-f). These data indicate that nCDase -/- does not prevent renal function loss 








C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9 mg/kg 
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected (subQ) 1 
day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were sacrificed 72 
hours following the final dose. (A) BUN levels were determined from serum. (B) NGAL 
levels were measured from the urine. (C) Kim-1 mRNA expression was measured via qRT-
PCR analysis of renal cortex. (D) Percent body weight change was tracked throughout 
RLDC as a measure of overt toxicity. WT indicates wild type mice, HET indicates nCDase -
/+ mice, KO indicates nCDase -/- mice. * signifies statistically different than vehicle treated 
WT mice. + signifies statistically different than vehicle treated HET mice. ^ signifies 
statistically different than vehicle treated KO mice. 






C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9 
mg/kg cisplatin or normal saline once a week for four weeks. 500 μl saline was 
injected (subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. 
Mice were sacrificed 72 hours following the final dose. Renal histological changes 
were assessed on H&E and PAS stained sections 5μm thick. (A) Tubular necrosis, (B) 
loss of proximal tubule brush borders, (C) proximal tubule cast formation, (D) tubule 
degeneration, (E) inflammatory cells, (F) widening of interstitium, (G) tubule dilation, 
and (H) tubular regeneration were assessed as markers of histological changes. 
Scoring of the sections was performed in a blinded manner by renal pathologist Dr. 
Megyesi using a scale of 0-4 (0=not present, 1=mild, 2=moderate, 3=severe, and 
4=very severe renal histological changes in the proximal tubules). WT indicates wild 
type mice, HET indicates nCDase -/+ mice, KO indicates nCDase -/- mice. * signifies 
statistically different than vehicle treated WT mice. + signifies statistically different than 
vehicle treated HET mice. ^ signifies statistically different than vehicle treated KO 
mice. 
 






C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9 
mg/kg cisplatin or normal saline once a week for four weeks. 500 μl saline was 
injected (subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. 
Mice were sacrificed 72 hours following the final dose. Relative mRNA expression of 
(A) TNFα, (B) IL6, (C) MCP-1, (D) CXCL1, (E) iNOS, and (F) Arg-1 were measured via 
real-time qRT-PCR. WT indicates wild type mice, HET indicates nCDase -/+ mice, KO 
indicates nCDase-/- mice. * signifies statistically different than vehicle treated WT mice. 
+ signifies statistically different than vehicle treated HET mice. ^ signifies statistically 
different than vehicle treated KO mice. 
Figure 14. nCDase inhibition does not alter inflammatory cytokine production or 
macrophage involvement in RLDC. 
62 
 
nCDase inhibition does not protect from development of fibrosis following 
RLDC. Previously, it had been shown that RLDC leads to collagen deposition 
and development of interstitial fibrosis.[57] We evaluated the development of 
fibrosis in wild type and nCDase -/- mice following RLDC using several methods. 
We detected levels of fibronectin expressed in the renal cortex using western 
blot. Our results suggest fibronectin expression is induced in both wild type and 
nCDase -/- mice in a similar fashion (Fig 15a). Sirius red fast green staining was 
also done to evaluate collagen deposition. In this stain, all collagen is dyed red 
while non-collagenous proteins are dyed green. Following RLDC, we saw similar 
amounts of collagen deposition in both wild type and nCDase -/- treated mice 
(Fig 15b). Fibrosis was also assessed by the pathological measure of widening of 
the interstitium. There was no difference in this measure among nCDase -/-, 
nCDase -/+, and wild type mice treated with cisplatin (Fig 13f). Interestingly, 
pathological assessment revealed our C57BL/6 mice may develop lower levels of 
fibrosis than what we’ve observed in FVB mice previously.[57] These data 









C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 9 mg/kg 
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected 
(subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were 
sacrificed 72 hours following the final dose.  (A) Protein expression of fibronectin in 
the renal cortex was evaluated via western blot. (B) Sirius red fast green staining was 
performed on nCDase -/- and wild type mice. WT indicates wild type mice, KO 
indicates nCDase-/- mice.  
Figure 15. nCDase inhibition does not alter fibronectin expression or collagen 
deposition following RLDC. 
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nCDase inhibition no longer attenuates cisplatin-induced ER stress. Having 
previously observed that nCDase -/- mice were resistant to ER stress in the high-
dose cisplatin model, we wanted to evaluate if this protection persisted in the 
RLDC model. We evaluated protein expression of ER stress markers CHOP, 
JNK, and NF-κB. Our data indicate that ER stress is induced in the RLDC model 
and nCDase inhibition does not block this induction (Fig 16). This suggests that 
RLDC employs different mechanisms of activating ER stress than what has 







C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 9 mg/kg 
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected 
(subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were 
sacrificed 72 hours following the final dose.  (A) Protein expression of the indicated 
ER stress markers from the renal cortex was evaluated via western blot. WT indicates 
wild type mice, KO indicates nCDase-/- mice. 





 This study evaluates the role of neutral ceramidase (nCDase) in an in vitro 
system as well as in vivo in two different models of CDDP-KI. In vitro, nCDase 
knockout in mouse embryonic fibroblasts (MEFs) promoted increased autophagy 
and resistance to nutrient deprivation induced cell death. Our results in vivo 
indicate that nCDase knockout offers protection from high-dose cisplatin induced 
acute kidney injury (AKI) by preventing ER stress and apoptotic cell death. In the 
repeated low dose cisplatin (RLDC) model, nCDase knockout does not provide 
protection from kidney injury and development of fibrosis. nCDase knockout also 
does not block ER stress induction in the RLDC model.  
These results indicate the importance of testing potential nephroprotective 
agents in both models of AKI and chronic kidney disease (CKD). It has been 
speculated that the RLDC model of injury employs the same mechanisms as the 
standard high-dose model. Here, we demonstrate that that is not likely the case. 
If the same mechanism of nephrotoxicity was produced in both models, nCDase 
knockout would have been protective in RLDC. The lack of protection in this 
model can give us clues into what mechanisms may be unique to RLDC induced 
nephrotoxicity.  
In the high-dose model, AKI development is dependent on cell death. We 
have established nCDase knockout blocks cell death in both in vitro models of 
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stress and in vivo in the high-dose model of cisplatin injury. Therefore, nCDase 
knockout provides protection from high-dose cisplatin. Previously, the RLDC 
model has not been shown to induce large levels of apoptosis or necrosis.[58] In 
this study, apoptosis was not measured but high levels of tubular necrosis were 
observed by pathology. We do not believe the driving pathology in RLDC induced 
fibrosis is cell death, but it could be a side effect of CKD development. In the 
high-dose model, cell death is the cause of AKI development. In the RLDC 
model, we believe cell death may be an effect of CKD development. Other 
studies have demonstrated how repeated sublethal injuries can lead to different 
renal outcomes than what is observed in acute models of kidney injury.  
Grgic et. al. examined how multiple sublethal insults to tubule epithelial 
cells promotes interstitial fibrosis and other CKD pathologies. They utilized renal 
epithelial cells expressing a diphtheria toxin receptor. Administration of diphtheria 
toxin resulted in specific renal epithelial cell death. Using this model, they 
demonstrated that a large, acute insult to tubule cells led to an inflammatory 
response and tubule cell proliferation allowing for complete recovery. With 
repeated, lower levels of injury they observed that the kidney underwent 
maladaptive repair followed by development of fibrosis and glomerulosclerosis. 
They speculated that repeated injury caused tubule cells to lose their replicative 
capacity and resulted in either senescence or a prolonged dedifferentiated 
state.[74] Cell cycle G2/M arrest has been identified as a contributor to fibrotic 
outcomes in renal models of injury. G2/M cell cycle arrest is also associated with 
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high levels of JNK signaling and secretion of profibrotic cytokines such as 
TGFβ.[21]  
Our current and past studies indicate that RLDC may also be causing cell 
cycle arrest and senescence. We see increased p-JNK protein expression (Fig 
16)[58] and TGFβ mRNA expression [58] with RLDC. We have also observed in 
this study (data not shown) and in the past [58] that RLDC causes increased 
mRNA expression of cyclin dependent kinase inhibitor 2a (CDKN2A), a known 
marker of cellular senescence. Therefore, we hypothesize that RLDC induced 
fibrosis is being driven by G2/M cell cycle arrest of tubule cells as they attempt to 
proliferate and repair renal damage. 
More studies are needed to verify whether tubule cells in the RLDC model 
are undergoing cellular senescence. We also need to examine levels of cell 
death at earlier timepoints in RLDC. These studies will help determine when 
senescence occurs and what cells are responsible. It could be that initially injured 
tubule cells remain and senesce, or there could be an initial cell death response 
to injury followed by uninjured tubule cell dedifferentiation and replication that is 
impaired upon repeated insults. 
Another possibility for the differences in nCDase knockout outcomes in 
high-dose cisplatin and RLDC could be due to varied roles of autophagy in acute 
and chronic kidney injury. In the acute model of cisplatin injury, autophagy has 
been shown to be protective. Takahashi et. al. demonstrated that high-dose 
cisplatin treatment led to upregulation of autophagy in the kidney. They then 
treated mice with proximal tubule specific autophagy deficiency and found that 
69 
 
they were more sensitive to injury. They also found that autophagy deficient mice 
had increased DNA damage, p53 activation, protein aggregation, and apoptosis 
following cisplatin treatment.[70] In this study, it is clear that autophagy protects 
against cellular damage induced by high dose cisplatin. Therefore, nCDase 
knockout would provide protection via upregulation of autophagy. 
In chronic models of kidney injury, the role of autophagy is less well 
defined. Nam et. al. made use of mice with distal tubule specific conditional 
knockout of autophagy related 7 (Atg7). These mice had deficient autophagy in 
the renal distal tubule cells compared to controls. Following unilateral ureteral 
obstruction, these mice had increased levels of renal fibrosis. Distal tubule 
autophagy deficiency was also associated with increased TGFβ expression.[75] 
In contrast to this study, Livingston et. al. used mice with a proximal tubule 
specific conditional knockout of Atg7. They found that mice deficient in proximal 
tubule autophagy had decreased levels of renal fibrosis following unilateral 
ureteral obstruction. They also saw decreased levels of renal fibrosis in mice 
treated with pharmalogical inhibitors of autophagy, chloroquine and 3-
methyladenine, prior to injury. Interestingly, this group saw no effect on TGFβ 
expression in autophagy impaired groups following injury.[76] These studies and 
others indicate that the role of autophagy in renal fibrosis may be context and 
cell-type dependent.[52] 
There are several experiments we could do in the future to determine the 
role of autophagy in our RLDC model. First, we must examine how RLDC alters 
autophagy. We could treat a GFP-LC3 mouse with RLDC and observe 
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autophagic flux at different time points. Once we determine how RLDC influences 
autophagy, we could make use of both pharmalogical inhibitors and conditional 
knockout mice to inhibit autophagy at different points of RLDC. Following 
inhibition we could examine outcomes of renal fibrosis and myofibroblast 
production to determine what role autophagy may be playing in disease 
progression. 
There is also a need to evaluate ER stress induction in both the high-dose 
and RLDC models. ER stress describes a disruption in ER homeostasis involving 
accumulation of misfolded proteins within the ER. This results in activation of the 
unfolded protein response (UPR) or cell death. The UPR is activated in an 
attempt to restore physiological function to the ER. However, long term activation 
of UPR can lead to permanent functional changes.[77] 
In this study, we demonstrated that nCDase knockout was sufficient to 
block ER stress induction in the high-dose model. In the RLDC model, nCDase 
knockout no longer blocked this induction. This suggests that there are different 
activators of ER stress in these models. Induction of ER stress in the RLDC 
model also appears to be occurring independently of cell death. This suggests 
that there is an adaptive response to ER stress in the RLDC model.  
ER stress involves several complex signaling cascades. There are three 
main proteins thought of as activators of ER stress: pancreatic endoplasmic 
reticulum kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating 
transcription factor 6 (ATF6). Each of these proteins trigger pathways involved in 
regulation of UPR and apoptotic responses.[77] We hypothesize that the extent 
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of activation in each of these arms may differ in high-dose cisplatin model and 
the RLDC model. This may account for the differential ER stress activation in 
nCDase knockout mice. It may also account for the difference in ER stress 
outcomes.[78] Future studies aimed at understanding the different drivers of ER 
stress in the two models are needed. 
Once activated, ER stress can lead to outcomes ranging from apoptosis to 
adaptation. Responses to ER stress depend on both the amount of cellular 
damage done as well as the length of time the insult persists. With acute insults, 
cells only need to withstand stress for a short period of time. Recovery depends 
on how quickly the cell can mount the UPR and clear accumulated unfolded 
proteins. Following clearance cellular function can return to normal. With chronic 
stress, the cell must undergo a functional change that is more permanent. This 
functional change and prolonged UPR allows cells to adapt to the chronic stress 
and escape cell death.[78] 
We hypothesize that in RLDC, tubule cells undergo functional changes in 
order to adapt to chronic ER stress. This adaptive response likely involves 
transcriptional upregulation of genes involved in protein folding and processing 
as well as alteration of metabolic function.[78] Chronic ER stress has previously 
been linked to CKD progression.[79] One study demonstrated that inhibition of 
ER stress following renal ischemia-reperfusion prevented development of 
fibrosis.[80] Future studies are needed utilizing the RLDC model in which ER 
stress is inhibited to determine its role in fibrosis development. 
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Literature also reports a close relationship between ER stress and 
autophagy. There is evidence to support ER stress induction and inhibition of 
autophagy.[51] The UPR has been shown to induce autophagy through IRE1α 
and PERK signaling. This induction is thought to act as a pro-survival response, 
helping clear damaged cellular debris and restore ER homeostasis. However, it 
has also been demonstrated that ER stress induced autophagy can mediate cell 
death through caspase 8 activation.[77] In the high-dose cisplatin model, it is 
possible that the upregulation of autophagy in nCDase knockout mice facilitates 
resistance to ER stress induction. In the RLDC it is less clear how ER stress and 
autophagy are being regulated. Future studies aimed at understanding the role of 
autophagy in the RLDC model and the relationship between autophagy and ER 
stress are needed. 
This study reveals how nephroprotective agents can have differential 
success in the high-dose cisplatin model and the RLDC model due to the 
inherent biological differences in these two models in the induction of cell 
death/senescence, ER stress induction and response, and autophagy. 
Evaluating the success of different therapeutic strategies in these models may 
help shed light on the different nephrotoxic mechanisms employed by high-dose 
cisplatin and RLDC treatment.  
It is important to take into account both acute and chronic renal injury 
when developing nephroprotective agents. Patients exhibit a wide range of 
response to cisplatin in the clinic. Some develop AKI after a single low dose while 
others may receive multiple doses without displaying signs of clinical AKI. 
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Developing an understanding of the biological processes occurring in both the 
high-dose cisplatin and RLDC models will help us understand the pathological 
processes occurring in all categories of patients. This will lead to better treatment 





Cisplatin is a commonly used chemotherapeutic agent with dose limiting 
nephrotoxicity. 10-20% of cancer patients will receive cisplatin as part of their 
treatment regimen. 30% of these patients will develop acute kidney injury (AKI), 
or a rapid decline in renal function. Even patients that do not develop AKI by 
clinical standards are still at risk for long term declines in renal function. 
Development of kidney injury greatly increases risk of mortality and development 
of chronic kidney disease (CKD). 
AKI is associated with high levels of tubule cell death, robust inflammation, 
and vascular damage. This type of injury has been experimentally modeled by 
giving mice a single, high dose of cisplatin. Mice do not survive longer then 3-4 
days after treatment. CKD is associated with interstitial fibrosis, chronic 
inflammation, and vascular rarefaction. Recent studies have brought to light the 
interconnectedness of AKI and CKD through processes of maladaptive repair. In 
order to develop better nephroprotective agents we must use models that allow 
for study of this progression following cisplatin treatment. Our repeated low dose 
cisplatin (RLDC) model utilizes 4 weekly low doses of cisplatin that enable mice 
to survive up to 6 months after treatment. This allows for evaluation of long-term 
progression to CKD. 
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We used both the high-dose cisplatin and RLDC models to assess the 
effects of neutral ceramidase (nCDase) on renal injury. We found that nCDase 
knockout mice were protected from AKI development in the high-dose cisplatin 
model. In contrast, nCDase knockout mice were not protected from development 
of renal fibrosis in the RLDC model. These experiments demonstrate that the 
high-dose cisplatin and RLDC models utilize different mechanisms of 
nephrotoxicity. While the high-dose cisplatin model has been well characterized, 
less is known about the RLDC model. Future studies will be aimed at further 
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